4Q Revenues: $289.2 million (+3%)
4Q Earnings: $19.1 million (+4%)
FY Revenues: $1.2 billion (+3%)
FY Earnings: $102.8 million (+6%)
Comments: Research Models and Services (RMS) segment sales were flat at $172.3 million in the quarter, and $707.1 million for the year, up 2%. Preclinical Services (PCS) segment sales were $117.0 million in the quarter, up 8%, led by demand from mid-tier biotechnology clients, as well as continued growth of global key accounts, and for the year sales were $458.4 million, up 6%.